Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. Its lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. TTI-0102 has been developed to address the obstacles facing previous thiol-based drugs, their short half-lives and side effects. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism that eliminates the spike in the immediate release of cysteamine that is commonly linked to GI side effects. TTI-0102â€™s initial applications are for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, Leigh syndrome, Rett syndrome and pediatric Nonalcoholic steatohepatitis.

Employees

Sector

Biotechnology & Medical Research

More about the company

Net sales - Rate of surprise

Company calendar

Market Closed - OTC Markets 09:30:16 2026-08-24 am EDT			5-day change	1st Jan Change
0.4199 ^USD	-0.02%		-.--%	-28.03%

Aug. 06	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Jul. 13	Thiogenesis Therapeutics Receives Fda Rare Pediatric Disease Designation for Tti-0102 for the Treatment of Leigh Syndrome	CI

Market Cap	34.99M 25.36M 21.83M 20.51M 18.76M 2.41B 35.16M 243M 94.01M 1.23B 95.31M 93.25M 3.9B	P/E 2024	-8.65x	P/E 2025	-4.25x
Enterprise Value	33.37M 24.19M 20.83M 19.56M 17.9M 2.3B 33.54M 232M 89.67M 1.17B 90.9M 88.95M 3.72B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	85.91%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Toronto S.E.	TTI	Delayed
OTC Markets	TTIPF	Delayed
Deutsche Boerse AG	Q8M	Delayed

Aug. 06	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Jul. 13	Thiogenesis Therapeutics Receives Fda Rare Pediatric Disease Designation for Tti-0102 for the Treatment of Leigh Syndrome	CI
Jul. 13	Thiogenesis Therapeutics' Treatment For Leigh Syndrome Receives FDA Rare Pediatric Disease Designation	MT
Jun. 17	Thiogenesis Therapeutics Appoints Gilad Aharon to its Board	MT
Jun. 17	Thiogenesis Therapeutics, Corp. Appoints Gilad Aharon to Its Board of Directors	CI
Jun. 03	Thiogenesis Therapeutics, Corp. announced that it has received CAD 9.07185 million in funding	CI
May. 25	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 11	Thiogenesis Therapeutics to Raise $8 Million Via a Non-Brokered Private Placement	MT
May. 11	Thiogenesis Therapeutics, Corp. announced that it expects to receive CAD 8 million in funding	CI
Apr. 30	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Apr. 29	Thiogenesis Therapeutics, Corp. Auditor Raises 'Going Concern' Doubt	CI
Feb. 02	Thiogenesis Therapeutics, Corp. Provides Program Update	CI
Jan. 23	Thiogenesis Therapeutics, Corp. Announces the Presentation of Interim Data from Its Phase 2 (Eu) Clinical Study of Tti-0102 in Patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes At Mitocon 2026	CI

Thiogenesis Therapeutics, Corp. Stock OTC Markets

Stocks

TTIPF

CA88410L1022

Biotechnology & Medical Research

Valuation : Thiogenesis Therapeutics, Corp.

Chart: Thiogenesis Therapeutics, Corp.

Latest news : Thiogenesis Therapeutics, Corp.

Analysts' recommendations : Thiogenesis Therapeutics, Corp.

Press Releases : Thiogenesis Therapeutics, Corp.

Quotes and Performance

Price Extremes

Managers and Directors : Thiogenesis Therapeutics, Corp.

Other Biotechnology & Medical Research

Financials

Company Profile

Net sales - Rate of surprise

Sep. 03	Thiogenesis Engages Brisco Capital for Investor Relations	NE
Jul. 13	Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome	NE
Jun. 17	Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors	NE
Jun. 03	Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million	NE
Jun. 01	Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares	NE

1 day	-0.02%
1 month	-0.02%
3 months	-0.02%
6 months	+9.63%
Current year	-28.03%

1 month	0.41	0.42
Current year	0.36	0.45
1 year	0.36	0.45
3 years	0	2.58
5 years	0	2.58
10 years	0	2.58

Manager	Title	Age	Since
Patrice Rioux CEO	Chief Executive Officer	75	2022-03-30
Brook Riggins CEO	Chief Executive Officer	60	-

Director	Title	Age	Since
Christopher Starr CHM	Chairman	73	2022-03-30
Patrice Rioux BRD	Director/Board Member	75	2022-03-30
Brook Riggins BRD	Director/Board Member	60	2018-05-02

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
THIOGENESIS THERAPEUTICS, CORP.	-0.02%	-.--%	-	-	25.34M
LONZA GROUP AG	-0.82%	-3.57%	-3.71%	+12.92%	48.41B
REVOLUTION MEDICINES, INC.	-1.29%	+0.85%	+411.90%	+546.06%	45.01B
IQVIA HOLDINGS INC.	-3.20%	-0.76%	+38.11%	+18.36%	44.07B
BEONE MEDICINES AG	-1.89%	-2.25%	+2.83%	+80.93%	40.73B
CELLTRION, INC.	-1.72%	-3.07%	+13.76%	+43.40%	33.21B
ASCENDIS PHARMA A/S	-0.17%	+2.68%	-	-	17.77B
MEDPACE HOLDINGS, INC.	-0.07%	-0.52%	+21.34%	+117.49%	16.5B
EUROFINS SCIENTIFIC SE	-0.56%	-1.85%	+11.53%	+30.40%	14.45B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.68%	-2.60%	+71.21%	+37.36%	13.77B
Average	-1.24%	+0.20%	+70.87%	+110.87%	30.44B
Weighted average by Cap.	-1.54%	-0.12%	+86.33%	+131.34%

	2024	2025
Net sales	-	-
Net income	-3.15M -2.28M -1.96M -1.84M -1.69M -216M -3.16M -21.86M -8.45M -111M -8.57M -8.38M -351M	-7.43M -5.38M -4.63M -4.35M -3.98M -511M -7.46M -51.61M -19.95M -261M -20.23M -19.79M -829M
Net Debt	-3.85M -2.79M -2.4M -2.26M -2.06M -265M -3.87M -26.74M -10.34M -135M -10.48M -10.26M -429M	-1.62M -1.17M -1.01M -947K -867K -111M -1.62M -11.23M -4.34M -56.83M -4.4M -4.31M -180M